Insilicos, a Seattle-based company that makes software for drug researchers, has received a $400,000 grant from the National Institutes of Health to study a statistical method for predicting disease. The grant will support the company’s work on Least Angle Regression, says Insilicos president Erik Nilsson, in an e-mail. This is the second grant for Insilicos since December, when the company received a $900,000 award from the NIH to study a blend of statistical models.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
